Evolus, Inc.
General ticker "EOLS" information:
- Sector: Health Care
- Industry: Drug Manufacturers - Specialty & Generic
- Capitalization: $463.4M (TTM average)
Evolus, Inc. does not follow the US Stock Market performance with the rate: -20.4%.
Estimated limits based on current volatility of 3.7%: low 6.04$, high 6.51$
Factors to consider:
- Total employees count: 332 (+21.6%) as of 2024
- US accounted for 95.1% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Significant losses, Capital raising, Geopolitical risks, Strategic risks and growth management, Key executive dependency
- Price in estimated range
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [4.09$, 9.67$]
- 2026-12-31 to 2027-12-31 estimated range: [4.05$, 9.47$]
Financial Metrics affecting the EOLS estimates:
- Negative: with PPE of -13.4 at the end of fiscal year the price was high
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Negative: negative Net income
- Negative: Industry earnings per price (median), % of 0 <= 0
Short-term EOLS quotes
Long-term EOLS plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $197.83MM | $259.10MM | $297.18MM |
| Operating Expenses | $247.06MM | $293.51MM | $334.78MM |
| Operating Income | $-49.23MM | $-34.41MM | $-37.60MM |
| Non-Operating Income | $-12.28MM | $-15.35MM | $-13.36MM |
| Interest Expense | $13.83MM | $18.73MM | $19.69MM |
| R&D Expense | $15.43MM | $9.17MM | $9.58MM |
| Income(Loss) | $-61.51MM | $-49.76MM | $-50.96MM |
| Taxes | $0.18MM | $0.66MM | $0.68MM |
| Net Income(Loss)* | $-61.69MM | $-50.42MM | $-51.64MM |
| Stockholders Equity | $-20.69MM | $5.52MM | $-23.11MM |
| Inventory | $11.00MM | $12.16MM | $26.96MM |
| Assets | $189.00MM | $232.57MM | $225.87MM |
| Operating Cash Flow | $-34.01MM | $-18.00MM | $-42.27MM |
| Capital expenditure | $1.63MM | $1.47MM | $3.44MM |
| Investing Cash Flow | $-1.63MM | $-4.82MM | $-8.45MM |
| Financing Cash Flow | $44.64MM | $47.41MM | $17.34MM |
| Earnings Per Share** | $-1.08 | $-0.81 | $-0.80 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.